TYAN
TYAN® , an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings a variety of AI, cloud and storage server platforms incorporating the latest AMD EPYC™ 7003 Series processors in TYAN’s 2021 Server Solutions Online Exhibition beginning June 2nd .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005045/en/
“As the continued growth of using clouds for running HPC workloads, modern data center operators need to raise the bar for improved business outcomes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “With leadership performance and modern security features, TYAN’s 3rd Generation AMD EPYC processor-based platforms empower our customers to drive performance at a competitive price.”
Transport HX products deliver leadership compute in supercomputing and deep learning
Attendees will experience demonstrations on the latest AMD products and technologies in HPC, cloud, storage, and 5G halls at the 3D virtual environment. Leveraging 3rd Generation AMD EPYC processors, the Transport HX TN83-B8251 is a 2U dual-socket server with 16 DDR4-3200 DIMM slots, two half-height, half-length PCIe 4.0 x16 expansion slots for high-speed networking cards, and eight 3.5-inch SATA/NVMe U.2 hot-swap, tool-less drive bays. The platform supports up to four double-width GPU cards that can be easily scaled out to improve HPC and deep learning performance.
The Transport HX TS75A-B8252 is a 2U dual-socket server platform optimized for virtualization applications with support for 32 DDR4-3200/2933 DIMM slots and up to nine PCIe 4.0 x8 slots. The TS75A-B8252 accommodates 26 2.5-inch SATA hot-swap, tool-less drive bays with up to eight NVMe U.2 support by configuration. The Transport HX FT65T-B8030 is a 4U convertible tower server platform designed for cost-effective HPC applications. The system supports a single AMD EPYC 7003 Series processor, eight DDR4-3200 DIMM slots, eight 3.5-inch SATA, and two NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8030 supports four double-width PCIe 4.0 x16 slots for GPUs to accelerate HPC applications.
Transport CX lineup is designed for cloud and data analytics requiring large memory capacity
The Transport CX GC79-B8252 and Transport CX GC79A-B8252 are 1U dual-socket server platforms that are ideal for high-density data center deployment for a variety of memory-based computing applications. Both systems feature 32 DDR4-3200/2933 DIMM slots, two standard PCIe 4.0 x16 expansion slots, and an OCP 3.0 LAN mezzanine slot. The GC79-B8252 platform provides four 3.5-inch SATA and four 2.5-inch NVMe U.2 hot-swap, tool-less drive bays, while the GC79A-B8252 platform offers twelve 2.5-inch drive bays with up to twelve NVMe U.2 support.
The Transport CX GC68-B8036-LE and Transport CX GC68A-B8036 are cost-optimized single-socket cache server platforms featuring 16 DDR4-3200/2933 DIMMs, a pair of PCIe 4.0 x16 expansion slots and an OCP 2.0 LAN mezzanine slot in a 1U chassis. The GC68-B8036-LE accommodates four 3.5-inch SATA hot-swap, tool-less drive bays for large storage capacity and four 2.5-inch hot-swap, tool-less NVMe U.2 bays for application cache usage; the GC68A-B8036 offers twelve 2.5-inch hot-swap, tool-less drive bays with support for up to twelve NVMe U.2 devices for applications for high storage performance requirements.
The Transport CX TN73-B8037-X4S is a 2U multi-node server platform with four front-serviced compute nodes. Each node supports one AMD EPYC 7003 Series processor, four 2.5-inch hot-swap, tool-less NVMe/SATA drive bays, eight DDR4-3200 DIMM slots, three internal cooling fans, two standard PCIe 4.0 x16 expansion slots, two internal NVMe M.2 slots and one OCP 2.0 LAN mezzanine slot. The platform is suited for high-density data center deployments and targets scale-out applications with large numbers of nodes.
Transport SX lineup to deliver massive I/O and memory bandwidth for storage applications
The Transport SX TS65-B8253 is a 2U dual-socket hybrid software storage server for various datacenter and enterprise deployments supporting 16 DDR4-3200 DIMM slots and seven standard PCIe 4.0 slots. The platform offers twelve front 3.5-inch hot-swap, tool-less SATA drive bays with support for up to four U.2 NVMe SSDs, and two rear 2.5-inch hot-swap, tool-less SATA drive bays for boot drive deployment.
TYAN’s Transport SX TS65-S8036 and Transport SX TS65A-S8036 are 2U single-socket storage servers with support for 16 DDR4-3200/2933 DIMM slots, five PCIe 4.0 and one OCP 2.0 LAN mezzanine slots. The TS65-S8036 accommodates twelve front 3.5-inch and two rear 2.5-inch hot-swap, tool-less SATA drive bays for cloud storage applications, up to four NVMe U.2 devices are supported on the front twelve drive bays; the TS65A-S8036 offers 26 front and two rear 2.5-inch hot-swap, tool-less drive bays for high-performance data streaming applications, the 26 front drive bays can support up to 24 NVMe U.2 devices by configuration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom